SB
AMRX icon

Strategic Blueprint’s Amneal Pharmaceuticals AMRX Stock Holding History

Strategic Blueprint’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,000
Closed -$15K – 442
2021
Q2 		$15K Buy
+3,000
New +$17.1K ﹤0.01% 873

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Strategic Blueprint's AMRX Position: Q3 2021 in Review

Strategic Blueprint sold out of Amneal Pharmaceuticals (AMRX) in Q3 2021, closing a stake of 3,000 shares — an estimated $15K sold.

Strategic Blueprint first reported a position in AMRX in Q2 2021 and held it in 1 quarter. The position peaked at $15K in Q2 2021. 154 funds tracked by Wall St. Rank hold AMRX as of Q3 2021.

  • Strategic Blueprint reported no remaining Amneal Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Strategic Blueprint sold 3,000 Amneal Pharmaceuticals shares in Q3 2021, an estimated $15K.
  • Strategic Blueprint first reported a position in Amneal Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Strategic Blueprint's Amneal Pharmaceuticals position peaked at $15K in Q2 2021.
  • 154 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2021.

Based on Strategic Blueprint's 13F filing for Q3 2021, filed 12 Nov 2021.